The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
There are substantial data demonstrating increased endothelial dysfunction, inflammation and oxidative stress in patients with Autosomal dominant polycystic kidney disease (ADPKD), the association between serum uric acid level and endothelial dysfunction has not been elucidated yet in these patients. Therefore, in this study, the investigators aimed to examine the relationship between the uric acid level and the ED in normotensive ADPKD patients with preserved renal function.
| Condition |
|---|
|
Polycystic Kidney, Autosomal Dominant |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Cross-Sectional |
| Official Title: | Endothelial Dysfunction in Patients With Polycystic Kidney Disease |
- Measurement of asymmetric dimethylarginine (ADMA) and flow mediated dilatation (FMD) [ Time Frame: 4 months ] [ Designated as safety issue: No ]ADMA,FMD and uric acid measurements were performed to determine endothelial dysfunction in ADPKD patients
| Enrollment: | 150 |
| Study Start Date: | January 2012 |
| Study Completion Date: | April 2012 |
| Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
polycystic kidney ,no hypertension
The study evaluated the association of serum uric acid levels with endothelial dysfunction in early ADPKD patients with normal renal function
|
Detailed Description:
This is the first study to evaluate the relationship between uric acid and endothelial dysfunction in patients with early stage ADPKD
Eligibility| Ages Eligible for Study: | 20 Years to 60 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with early stage(preserved renal function) Autosomal dominant polycystic kidney disease (n = 91) from two academic medical center.We also excluded the patients with a previous diagnosis of hypertension, gout, diabetes, current use of oral antidiabetic medication, insulin, thiazide, allopurinol or uricosuric, or a fasting glucose level 126 mg/dl. In addition, the subjects with a history of smoking or current use of any anti-hypertensive medication and statins were excluded
Inclusion Criteria:
- ADPKD patients with normal renal function,
- Normotensive ADPKD patients
Exclusion Criteria:
- Patients with impaired kidney function,
- Atherosclerotic disorders,
- Diagnosis of hypertension, gout, diabetes,
- Using of insulin, thiazide, allopurinol or uricosuric drugs
Contacts and Locations More Information
No publications provided
| Responsible Party: | Ismail Kocyigit, TC Erciyes University Medical School, TC Erciyes University |
| ClinicalTrials.gov Identifier: | NCT01589705 History of Changes |
| Other Study ID Numbers: | Erciyes 2011/273 |
| Study First Received: | April 30, 2012 |
| Last Updated: | July 29, 2012 |
| Health Authority: | Sweden: Medical Products Agency |
Keywords provided by TC Erciyes University:
|
Uric acid polycystic kidney disease |
Additional relevant MeSH terms:
|
Kidney Diseases, Cystic Kidney Diseases Polycystic Kidney Diseases Polycystic Kidney, Autosomal Dominant Urologic Diseases Uric Acid |
Antioxidants Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Protective Agents Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 17, 2013